Our Stories

A growing public health challenge  

Lyme disease is the most common vector-borne disease in the United States and Europe. It’s estimated that 476,000 people are diagnosed and treated for Lyme disease in the United States each year and more than 132,000 cases are reported annually in European countries with surveillance systems. 

As with many global public health challenges, the growing prevalence of Lyme disease is intrinsically linked to environmental change. Lyme disease is caused by Borrelia bacteria, transmitted to humans through the bite of infected Ixodes ticks which are highly sensitive to temperature. Milder winters are improving the survival rates of ticks, particularly in northern and higher-altitude regions, while warmer conditions are extending the period during which ticks are active. As a result, tick populations are expanding into areas where they were previously unable to establish themselves, further enabling the spread of tick-borne diseases such as Lyme disease.  

Recognizing the impact on patients and society 

In the early stages, symptoms of Lyme disease such as fatigue, fever, and muscle or joint pain can be easily mistaken for flu-like symptoms. Although a bull’s eye rash at the site of the tick bite is a recognized sign, this does not appear in all patients and can also be difficult to detect. Importantly, if Lyme disease is not identified and treated early, the infection can progress to become increasingly debilitating.  

In more advanced stages, Lyme disease may affect the nervous system, the heart, or the joints, leading to complications that can be more difficult to manage. In fact, between 5-10% of people continue to have persistent symptoms following treatment, contributing substantially to the burden of Lyme disease, not only on the individual, but on healthcare systems and society.  

Why prevention matters 

When infections are prevented – complications never develop, and patients do not enter the healthcare system. This is where prevention delivers its greatest value. For difficult to treat and highly prevalent conditions such as Lyme disease, prevention represents more than incremental progress; it reflects a shift in approach from managing the consequences of infection, to reducing the risk of infection altogether. 

At the same time, developing effective preventative solutions is complex. As Lyme disease is caused by multiple Borrelia species, it requires an approach that can provide broad protection against different serotypes. Transmission via ticks – rather than directly between humans – adds further scientific complexity, as does the variability in infection risk across regions, seasons, and populations. These factors make research in this area more challenging, often requiring multi-season studies across diverse populations – increasing complexity. Despite these challenges, prevention remains critical as the most effective strategy to mitigate risk.  

Looking ahead: shifting the paradigm  

Addressing Lyme disease effectively will require a shift in how it is understood and prioritized. Historically, Lyme disease has often been viewed as a treatable condition, which has reduced the urgency around prevention. However, given the complexity of diagnosis and the potential for long-term complications, this perspective is increasingly outdated.  

Greater emphasis on prevention – alongside improved surveillance and a more integrated understanding of the link between environmental and human health – will be essential. Strengthening awareness, among both healthcare professionals and the public, will also play a key role, particularly as the geographic footprint of the disease continues to expand.  

World Immunization Week serves as a timely reminder that the most effective public health interventions are often those that prevent disease before it begins. With continued research, innovation, and a prevention-first mindset, there is a clear opportunity to reduce the impact of  infectious diseases in the years ahead.